![]() Among these, 358,781 (8.9%) specimens tested positive, including 349,050 (97.3%) for influenza A and 9,731 (2.7%) for influenza B viruses. During the 2022-23 influenza season, the included clinical laboratories tested 4,023,390 respiratory specimens for influenza viruses using clinical diagnostic tests. ![]() World Health Organization (WHO) collaborating laboratories and National Respiratory and Enteric Virus Surveillance System (NREVSS) laboratories, which include both clinical and public health laboratories throughout the United States, contribute to virologic surveillance for influenza (1). It also includes the composition of the Northern Hemisphere 2023–24 influenza vaccines and a brief update on influenza activity occurring during the summer of 2023 in the Southern Hemisphere. This report describes the extent and timing of influenza activity in the United States during the 2022-23 influenza season (Octo– September 9, 2023) as reported to CDC by clinical and public health laboratories, outpatient providers, emergency departments, hospitals, vital statistics offices, and public health departments. Influenza A(H3N2) viruses were the predominant virus subtype circulating during the single wave of activity that peaked in late November and early December however, influenza A(H1N1)pdm09 and influenza B/Victoria viruses also were reported. Influenza activity in the United States during the 2022-23 season (Octo– September 9, 2023) was moderately severe and was characterized by activity that returned to pre-COVID-19 levels but occurred earlier than is usual. The Centers for Disease Control and Prevention (CDC) collects, compiles, and analyzes data on influenza viruses and associated morbidity and mortality in the United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |